Rebecca C Taylor1, Peter Richmond, John W Upham. 1. Telethon Institute for Child Health Research, Centre for Child Health Research, University of Western Australia, West Perth.
Abstract
BACKGROUND: There is intense interest in the interaction between microbial compounds and allergy. Although Toll-like receptor (TLR)-2 ligands derived from Gram-positive bacteria alter allergic sensitization in animal models, it is not clear what effect TLR2 ligands have on allergen-specific T-cell memory in human beings. OBJECTIVE: To determine whether in vitro exposure to TLR2 ligands modifies the immune response to house dust mite allergen (HDM). METHODS: Blood mononuclear cells were obtained from individuals both allergic (n = 23) and not allergic (n = 22) to HDM, and stimulated with HDM in the presence or absence of TLR2 ligands. RESULTS: In subjects allergic to HDM, IL-5 and IL-13 responses to HDM were inhibited by heat-killed Staphylococcus aureus, staphylococcal lipoteichoic acid, and the synthetic lipoprotein Pam3CSK4 (P < .005; all stimuli). Although the whole staphylococcal bacteria increased IFN-gamma responses, the purified TLR2 ligands lipoteichoic acid and Pam3CSK4 inhibited HDM-specific IFN-gamma synthesis. In contrast, TLR2 ligands had minimal effects on responses to HDM in subjects without allergy. TLR2 ligands induced upregulation of HLA-DR expression but did not inhibit antigen uptake or processing by antigen-presenting cells. CONCLUSION: Toll-like receptor 2 ligands inhibit allergen-specific T(H)2 responses in sensitized individuals. This effect appears to be mediated by the actions of TLR2 ligands on antigen-presenting cells, and at least for the purified TLR2 ligands does not involve the induction of a strong T(H)1 immune response. CLINICAL IMPLICATIONS: These findings provide an impetus for further preclinical studies examining the potential use of TLR2 ligands in allergic disease.
BACKGROUND: There is intense interest in the interaction between microbial compounds and allergy. Although Toll-like receptor (TLR)-2 ligands derived from Gram-positive bacteria alter allergic sensitization in animal models, it is not clear what effect TLR2 ligands have on allergen-specific T-cell memory in human beings. OBJECTIVE: To determine whether in vitro exposure to TLR2 ligands modifies the immune response to house dust mite allergen (HDM). METHODS: Blood mononuclear cells were obtained from individuals both allergic (n = 23) and not allergic (n = 22) to HDM, and stimulated with HDM in the presence or absence of TLR2 ligands. RESULTS: In subjects allergic to HDM, IL-5 and IL-13 responses to HDM were inhibited by heat-killed Staphylococcus aureus, staphylococcal lipoteichoic acid, and the synthetic lipoprotein Pam3CSK4 (P < .005; all stimuli). Although the whole staphylococcal bacteria increased IFN-gamma responses, the purified TLR2 ligands lipoteichoic acid and Pam3CSK4 inhibited HDM-specific IFN-gamma synthesis. In contrast, TLR2 ligands had minimal effects on responses to HDM in subjects without allergy. TLR2 ligands induced upregulation of HLA-DR expression but did not inhibit antigen uptake or processing by antigen-presenting cells. CONCLUSION:Toll-like receptor 2 ligands inhibit allergen-specific T(H)2 responses in sensitized individuals. This effect appears to be mediated by the actions of TLR2 ligands on antigen-presenting cells, and at least for the purified TLR2 ligands does not involve the induction of a strong T(H)1 immune response. CLINICAL IMPLICATIONS: These findings provide an impetus for further preclinical studies examining the potential use of TLR2 ligands in allergic disease.
Authors: D S Ferreira; R Annoni; L F F Silva; M Buttignol; A B G Santos; M C R Medeiros; L N S Andrade; C Y Yick; P J Sterk; J L M Sampaio; M Dolhnikoff; S E Wenzel; T Mauad Journal: Clin Exp Allergy Date: 2012-10 Impact factor: 5.018
Authors: Kui Shin Voo; Myriam Foglietta; Elena Percivalle; Fuliang Chu; Durga Nattamai; Megan Harline; Seung-Tae Lee; Laura Bover; Heather Y Lin; Veerabhadran Baladandayuthapani; David Delgado; Amber Luong; R Eric Davis; Larry W Kwak; Yong-Jun Liu; Sattva S Neelapu Journal: Int J Cancer Date: 2014-05-12 Impact factor: 7.396